

- The aim of this study was to evaluate the safety and intraocular pressure (IOP)-lowering efficacy after *ab interno* implantation of two Glaukos Trabecular Micro-Bypass iStent *inject* second generation devices in subjects with open angle glaucoma (OAG).
- Prospective, unmasked, multi-center, post-market trial involving 99 patients with OAG who, in spite of 2 or more topical ocular hypotensive medications, required additional IOP lowering therapy.
- Patients underwent implantation of two GTS400 stents in a stand-alone procedure.
- At 12 months postoperative, 66% achieved IOP ≤ 18 mmHg without medication, and 81% achieved IOP ≤ 18 mmHg with either a single medication or no medication.
- Preoperative medication burden was reduced in 86.9% of patients at 12 months. Postoperative complications occurred at a low rate and resolved without persistent effects.

This summary slide represents the opinions of the authors. Sponsorship for performing this study and payment of the article processing charges was provided by Glaukos Corporation, Laguna Hills, CA, USA. Editorial assistance in the preparation of this manuscript was provided by Jeannie Gifford Cecka, Clinical and Regulatory Consultant, and was funded by Glaukos. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).